With ‘breakthrough’ status and a handy nickname, BioMarin plots … – Endpoints News
Pharmacy Practice News |
With 'breakthrough' status and a handy nickname, BioMarin plots …
Endpoints News The FDA has handed out its breakthrough therapy designation for BioMarin's closely-watched gene therapy drug BMN 270 for hemophilia A. In their Q3 call on … FDA Gives Designations to Hemophilia Gene Therapies – Pharmacy … BioMarin's Gene Therapy for Hemophilia A Continues to Impress Hemophilia Gene Therapy Market Pipeline Analysis 2016 to 2021 … |
